Skip to main
ARGX
ARGX logo

argenx (ARGX) Stock Forecast & Price Target

argenx (ARGX) Analyst Ratings

Based on 28 analyst ratings
Buy
Strong Buy 39%
Buy 54%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Argenx has achieved breakeven on operating profit in the third quarter of 2024, with expectations for improving operating margins driven by increased sales and stabilized R&D spending. The company reported impressive growth with $737 million in global product net sales for the fourth quarter of 2024, reflecting a 29% quarter-over-quarter and 97% year-over-year increase, marking the 12th consecutive quarter of revenue growth fueled by its lead product, Vyvgart, and the newly approved formulation for Chronic Inflammatory Demyelinating Polyneuropathy. Argenx's commitment to innovation is evidenced by its robust pipeline and R&D investment strategy, which aims to sustain momentum and capitalize on the potential for future growth within the biopharmaceutical market.

Bears say

Argenx has reported a slight decline in R&D expenses, which fell 3.0% year-over-year to $297.2 million in 4Q23, indicating potential concerns regarding the sustainability of investment in key programs amidst financial uncertainties. The company faces multiple risks, including lower-than-expected growth in Vyvgart sales, potential safety concerns from ongoing trials, and increased competition, which could jeopardize its future revenue streams and hinder pipeline advancements. Furthermore, the financial outlook is further clouded by the ongoing challenges seen in the biopharmaceutical sector, exemplified by competitors experiencing revenue stagnation due to factors such as loss of exclusivity and difficulties in transitioning patients to new therapies.

argenx (ARGX) has been analyzed by 28 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 54% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About argenx (ARGX) Forecast

Analysts have given argenx (ARGX) a Buy based on their latest research and market trends.

According to 28 analysts, argenx (ARGX) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $602.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $602.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

argenx (ARGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.